News Center
Home > News Center > Content Pages
 
New Clinical Data Demonstrate Clinical Utility of Caris Molecular Intelligence Profiling to Aid Trea
2015-10-05
 
 

New Clinical Data Demonstrate Clinical Utility of Caris Molecular Intelligence Profiling to Aid Treatment Selection for Rare or Refractory Solid Tumors



IRVING, Tex., Sept. 28, 2015 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announces the presentation of new data from clinical research institutions in France and Lebanon that support the clinical utility and value of Caris Molecular Intelligence®, the company’s panomic comprehensive tumor profiling service, in facilitating treatment selection in patients with rare or refractory solid tumors. Results from the two studies were presented during poster sessions at the 2015 European Cancer Congress (ECC2015) in Vienna, Austria.

“Outcomes from these studies are further evidence that Caris’ multiplatform profiling service is informing selection of personalized treatment strategies for patients with various tumor types, including those that are difficult to treat,” said Sandeep K. Reddy, M.D., Chief Medical Officer at Caris Life Sciences. “Such advances are not limited to clinics in North America, but have practical implications for cancer patients around the world, as exemplified by these poster presentations at ECC2015.”


To Read more, CLICK HERE


 
>> Returns a list of pages
My Comments
     
 

0  Comments Currently

 
Related Category
Promotion Products
More
 
 
  • Partners
  • Links
USCAP  |   CAP  |   IAP  |   TPIS  |   ASC  |   CAP-ACP  |   ASIP  |   AMP  |   ASCP  |   CAPA  |  
Home  |  News  |  Journals  |  Cases  |  Lectures  |  Experts  |  Telepath  |  Research  |  Conferences  |  Job_Position  |  Books  |  Sponsors
2009-2015 All Rights Reserved GoPath Diagnostics, LLC.